Brodalumab in plaque psoriasis: A Canadian real-world retrospective analysis

Brodalumab, an IL−17 receptor A antagonist, is indicated for moderate-to-severe plaque psoriasis (PsO). However, there are limited real-world data specific to the Canadian setting. Gaudet et al. recently published in Dermatology and Therapy a real-world retrospective analysis evaluating the effectiveness of brodalumab in PsO.¹

The study included 2,482 patients with PsO enrolled in the PSP who received brodalumab between July 1, 2018, and June 30, 2022. The primary outcome was the proportion of patients achieving PASI 100. Secondary outcomes included the proportion of patients achieving PASI 90, mean PASI, BSA, and DLQI scores. 

Key learnings

In a subset of patients with data from baseline and at least one follow-up visit, 66.1% and 53.2% of patients achieved PASI 90 and PASI 100, respectively, within the first 3 months of treatment.

PASI 90 and PASI 100 rates were sustained beyond 24 months in 68.1% and 52.2% of patients, respectively.

Mean PASI scores reduced from 14.0 at baseline to 1.5, and mean DLQI decreased from 17.3 at baseline to 2.8 within the first 3 months. Mean BSA score reduced from 17.3% at baseline to 5.1% within the first 3 months.

Brodalumab was effective in achieving PASI 90 and PASI 100, and these rates were sustained over time; improvements in DLQI reflected positive changes in patients’ QoL. Future studies comparing brodalumab with other biologic therapies will help to guide PsO treatment strategies going forward.